Skip to main content

Catalyst Calendar

Scope

Wed, Aug 12, 2026

1 updates
AIM
8:44 AM

AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article

Article by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge Highlights Company’s investigational drug Ampligen® (rintatolimod) and its potential application as a broad-spectrum prophylactic or early-onset antiviral countermeasure in Ebola and its variants Access the article...

aimimmuno.com

Mon, Aug 10, 2026

1 updates
AIM
8:36 AM

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer

Completed Enrollment and Ampligen Dosing in Metastatic Pancreatic Cancer Phase 2 Trial, Positioning Company for Key Clinical Milestones Through Early 2027 Pancreatic Cancer Remains Strategic Priority as AIM Advances Toward Planned Phase 3 Development While Seeking Select Government-Funded Infectious Disease Initiatives in Ebola OCALA, Fla., Aug....

Enrollment • Phase 2Enrollment milestone Mon, Aug 10, 2026aimimmuno.com

Mon, Aug 3, 2026

1 updates

Tue, Jul 7, 2026

1 updates

Wed, Jun 24, 2026

1 updates
AIM
8:29 AM

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

Recent Clinical Progress, Enrollment Achievements, Expanded Intellectual Property Portfolio and Strengthened Financial Position Support a Potentially Transformative 12-Month Value Creation Opportunity OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...

Enrollment • Phase 2Enrollment milestone Wed, Jun 24, 2026aimimmuno.com

Mon, Jun 22, 2026

1 updates
AIM
8:45 AM

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

Live webcast on Wednesday, June 24th at 2:40 PM ET OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026. Details for the presentation are as follows: Date and Time:...

aimimmuno.com

Thu, Jun 18, 2026

1 updates

Mon, Jun 15, 2026

1 updates

Tue, Jun 9, 2026

1 updates
AIM
9:30 AM

AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”), today announced that it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gross proceeds of approximately $2.65 million, before deducting...

aimimmuno.com

Mon, Jun 8, 2026

1 updates
AIM
8:33 AM

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...

Interim Data • Phase 2Primary endpoint evaluation Tue, Dec 1, 2026aimimmuno.com

Thu, Jun 4, 2026

1 updates
AIM
8:55 AM

AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness

Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen’s previously published antiviral research Discussion highlights Ampligen’s immune-modulating mechanism, prior Biosafety Level 4 findings and potential applicability across emerging viral threats New Ebola-focused corporate presentation...

aimimmuno.com

Mon, Jun 1, 2026

1 updates